reports
- Carole Braudeau
- Carole Braudeau
- ING Helpdesk
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Mathijs Geerts Danau
UCB Detailed results from Fintepla in CDD strengthen epilepsy franchis...
UCB presented detailed results of the positive phase 3 GEMZ study with Fintepla in CDKL5 deficiency disorder (CDD). The drug showed an estimated 52.7% median reduction in countable motor seizure frequency (CMSF) compared with placebo during a 14 week titration and maintenance period and a favourable safety profile. We view this as highly encouraging in this refractory epilepsy population. Given the infantile onset of CDD, we will be curious to see as of which age, patients could be included in t...
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 202...
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025 High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time Mechelen, Belgium; December 8, 2025, 07:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy candidate, GLPG5101, during an oral presentation (#662) at the 67th American Society of Hematol...
Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH...
Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH 2025 Hoge percentages complete respons en minimale residuele ziekte (MRD)-negativiteit, met duurzame responsen, bij hoog-risico mantelcellymfoom (MCL) met GLPG5101, een verse, early-memory verrijkte CAR T-celtherapie met een vein-to-vein-tijd van 7 dagen Mechelen, België; 8 december 2025, 07:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde nieuwe en geüpdatete fase 2-gegevens aan uit de lopende ATALANTA-1-studie met haar CD19 CAR T-celtherapiekandidaat GLPG5101, tijdens een mondelinge presentatie (#662) op de 67s...
YAS Healthcare signs contract for a Proteus®ONE solution, the first pr...
YAS Healthcare signs contract for a Proteus®ONE solution, the first proton therapy system to be installed in Dubai, UAE Louvain-La-Neuve, Belgium, December 8, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today it has signed a contract with YAS Healthcare, a subsidiary of DAS Holding, to install a Proteus®ONE1 compact proton therapy solution to be located in Dubai, United Arab Emirates (UAE). With the acquisition of this Proteus®ONE ...
Ageas to take full ownership of AG Insurance and formalise long term p...
Ageas to take full ownership of AG Insurance and formalise long term partnership with BNP Paribas Ageas to take full ownership of AG Insurance and formalise long term partnership with BNP Paribas Ageas SA/NV (“Ageas”, the “Group”) today announced the acquisition of the outstanding 25% stake in its Belgian subsidiary AG Insurance SA/NV (“AG”) from BNP Paribas Fortis SA/NV (“BNP Paribas Fortis”). This transaction further accelerates and upgrades Ageas’s Elevate27 strategic and financial ambitions for the second time this year. Additionally, Ageas and BNP Paribas SA (“BNP Paribas”) reconfirm...
Ageas prend la pleine propriété d’AG Insurance et formalise un partena...
Ageas prend la pleine propriété d’AG Insurance et formalise un partenariat à long terme avec BNP Paribas Ageas prend la pleine propriété d’AG Insurance et formalise un partenariat à long terme avec BNP Paribas Ageas SA/NV (« Ageas », le « Groupe ») annonce aujourd’hui l’acquisition de la participation de 25 % du capital en circulation dans sa filiale belge AG Insurance SA/NV (« AG ») auprès de BNP Paribas Fortis SA/NV (« BNP Paribas Fortis »). Cette transaction accélère et renforce les ambitions stratégiques et financières d’Ageas dans le cadre du plan Elevate27, pour la deuxième fois cett...
Ageas wordt 100% eigenaar van AG en formaliseert lange-termijnpartners...
Ageas wordt 100% eigenaar van AG en formaliseert lange-termijnpartnerschap met BNP Paribas Ageas wordt 100% eigenaar van AG en formaliseert lange-termijnpartnerschap met BNP Paribas Ageas SA/NV (“Ageas”, de “Groep”) kondigt vandaag de overname aan van het uitstaande belang van 25% in haar Belgische dochteronderneming AG Insurance SA/NV (“AG”) van BNP Paribas Fortis SA/NV (“BNP Paribas Fortis”). Met deze transactie versnelt en versterkt Ageas zijn strategische en financiële ambities binnen Elevate27 voor de tweede keer dit jaar. Daarnaast herbevestigen Ageas en BNP Paribas SA (“BNP Paribas”...
YAS Healthcare signe un contrat pour une solution Proteus®ONE, le prem...
YAS Healthcare signe un contrat pour une solution Proteus®ONE, le premier système de protonthérapie à Dubaï Louvain-la-Neuve, Belgique, le 8 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, annonce aujourd'hui avoir signé un contrat avec YAS Healthcare, une filiale de DAS Holding, pour l'installation d'une solution compacte de protonthérapie Proteus®ONE1 à Dubaï, aux Émirats arabes unis (UAE). Avec l'acquisition de ce système,...
- Ahmed Ben Salem
- Baptiste Salaville
- Oddo Sustainability Team
- Martial Descoutures
- Martial Descoutures
- Ahmed Ben Salem
- Baptiste Salaville
- Oddo Sustainability Team
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
- Jacob Mekhael
UCB Announces another FY25 guidance upgrade
UCB announced an additional upgrade to its FY25 financial guidance, where it now expects revenue to exceed € 7.6b, representing +24% y/y (previously at least € 7b), and adj. EBITDA margin to be higher than 31% (previously at least 30%). This is the company's second guidance upgrade this year and shows that UCB's commercial momentum continues its upward trajectory supported by its 5 key growth drivers, including lead product Bimzelx which saw strong momentum in HS, as well as a favourable payer m...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List How to start 2026?
How to start 2026? We have selected for the KBC Securities Dynamic Top Pick List 12 large-cap companies — AB InBev, Aedifica, Argenx, ASMi, Azelis, DEME, D'Ieteren, Shurgard, Sofina, Vopak, WDP, and Wolters Kluwer — along with 3 small and mid-cap names (under €1.5bn in market capitalization): Corbion, EVS, and IBA. So, going into 2026, we maintain a balanced approach in our Dynamic Top Pick List, featuring 8 cyclical and 6 defensive stocks, with a particular emphasis on value stocks that have b...
EVS EVS BROADCAST EQUIPMENT SA
DIE D'IETEREN SA
SOF SOFINA SA
ASM ASM INTERNATIONAL N.V.
IBAB ION BEAM APPLICATIONS SA
ROYAL VOPAK NV
AED AEDIFICA SA
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.